tirzepatide mastery course
Unit 11 of 12

Regulatory & Market Landscape

from FDA approval to the compounding crisis -- tirzepatide's place in the incretin revolution

The Business of Dual Agonism

Tirzepatide is not just a molecule -- it is the centerpiece of Eli Lilly's growth strategy, a regulatory test case for obesity drug approvals, and the catalyst for a legal battle over compounding pharmacies. Mounjaro and Zepbound together generated over $10 billion in 2024 revenue. Meanwhile, the FDA's decision to remove tirzepatide from the drug shortage list triggered lawsuits from compounders who had been filling demand at a fraction of the brand-name price. This unit covers the regulatory timeline, the compounding controversy, how tirzepatide compares to semaglutide in the market, and the next-generation drugs already in late-stage development.

Competitive Landscape

Compare tirzepatide against other incretin drugs across efficacy, safety, cost, and market positioning.

interactive landscape comparison
3
fda-approved indications (t2d may 2022, obesity nov 2023, osa dec 2024)
$10B+
combined mounjaro and zepbound revenue in 2024
28.7%
mean weight loss with retatrutide 12 mg at 48 weeks in phase 2 (next-generation triple agonist)
~10.5%
weight loss with orforglipron, eli lilly's oral small-molecule GLP-1 agonist (phase 3)
compounded products carried significant safety risks. Compounded tirzepatide used untested salt forms (tirzepatide sodium, tirzepatide acetate), had no FDA-mandated quality testing, and variable sterility and potency. The FDA declared the shortage resolved in October 2024, and enforcement against compounders began by March 2025.

key terms for this unit

R retatrutide next-generation drug
A triple GIP/GLP-1/glucagon receptor agonist from Eli Lilly currently in phase 3 (TRIUMPH program). Phase 2 data showed 28.7% mean weight loss at 12 mg over 48 weeks, exceeding tirzepatide's results.
O orforglipron next-generation drug
An oral small-molecule GLP-1 agonist from Eli Lilly. Not a peptide, taken daily by mouth. Approximately 10.5% weight loss in phase 3 -- lower than injectable tirzepatide but with oral convenience.
5 503a / 503b regulatory framework
Sections of the FD&C Act that permit compounding pharmacies to produce drugs during shortages. 503A covers state-licensed pharmacies; 503B covers outsourcing facilities. Enforcement discretion ended by March 2025 after the shortage was resolved.
S survodutide next-generation drug
A dual GLP-1/glucagon receptor agonist from Boehringer Ingelheim in phase 3 development. Unlike tirzepatide's GIP/GLP-1 combination, survodutide pairs GLP-1 with glucagon for potential advantages in MASH and liver disease.
F first-in-class regulatory designation
A regulatory designation for the first approved drug with a novel mechanism of action. Mounjaro's 2022 approval made tirzepatide the first-ever dual GIP/GLP-1 receptor agonist to reach the market.